Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-T with Mosunetuzumab and Polatuzumab for R/R Aggressive NHL
NCT05260957Phase 2Recruiting
- Start
- Dec 2022
- Primary completion
- Dec 2026
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of mosunetuzumab and polatuzumab vedotin in non-Hodgkin lymphoma (NHL). Started Dec 2022; status: recruiting.
02
Drugs
mosunetuzumabpolatuzumab vedotin
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT05260957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05260957.